Coherus BioSciences (CHRS) said Tuesday that it has agreed to divest its biosimilar drug Udenyca, which is based on Amgen's (AMGN) Neulasta, to Intas Pharmaceuticals for up to $558.4 million.
The company said the transaction includes an upfront payment of $483.4 million, as well as $75 million in potential net sales milestone payments.
Coherus said it plans to use a portion of the proceeds to fully repay its $230 million convertible notes due in April 2026, as well as to settle $49.1 million in Udenyca royalty obligations.
The deal is expected to be completed by the end of Q1.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。